We are live on ! Find out more
ACHL

Achilles Therapeutics
ACHL

Delisted

ACHL was delisted on the 20th of March, 2025.

Back to rankings

6 hedge funds and large institutions have $80.2K invested in Achilles Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

71% less funds holding

Funds holding: 21 → 6 (-15)

94% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 16

100% less capital invested

Capital invested by funds: $27.7M → $80.2K (-$27.6M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
6
Holders Change
-15
Holders Change %
-71.43%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
+$15.7K
2
GI
GAMMA Investing
California
+$1.05K

Top Sellers

Rank Fund Capital Flow
1
SP
Syncona Portfolio
Guernsey
-$12.6M
2
FIS
FCPM III Services
Netherlands
-$2.75M
3
RG
Redmile Group
California
-$1.83M
4
VPC
Vestal Point Capital
New York
-$1.71M
5
IC
Ikarian Capital
Texas
-$1.64M

ACHL Hedge Fund Activity: Q1 2025 in Review

6 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q1 2025, worth a combined $80.2K — down 100% from $27.7M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ACHL and 1 opened new positions — a net loss of 15 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was XTX Topco, adding an estimated $15.7K. The largest seller was Syncona Portfolio, exiting entirely with an estimated $12.6M sold.

  • 6 institutional investors held Achilles Therapeutics (ACHL) as of Q1 2025, down from 21 in Q4 2024.
  • Funds reported $80.2K of Achilles Therapeutics stock for Q1 2025, down 100% quarter-over-quarter.
  • 1 fund opened new Achilles Therapeutics positions in Q1 2025 and 16 closed out, a net change of -15 holders.
  • The largest Achilles Therapeutics buyer in Q1 2025 was XTX Topco, an estimated $15.7K added.
  • The largest Achilles Therapeutics seller in Q1 2025 was Syncona Portfolio, an estimated $12.6M sold.

Based on aggregated 13F filings for Q1 2025.